Advertisement
Canada markets open in 4 hours 7 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7327
    +0.0003 (+0.05%)
     

  • CRUDE OIL

    83.72
    +0.15 (+0.18%)
     

  • Bitcoin CAD

    87,972.05
    +512.62 (+0.59%)
     

  • CMC Crypto 200

    1,390.30
    -6.24 (-0.45%)
     

  • GOLD FUTURES

    2,363.60
    +21.10 (+0.90%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,726.50
    +159.00 (+0.91%)
     

  • VOLATILITY

    15.60
    +0.23 (+1.50%)
     

  • FTSE

    8,108.48
    +29.62 (+0.37%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6820
    -0.0001 (-0.01%)
     

Five Star Equities Issues New Research Reports on CLDN, PCYC, SPCB and VJET

ACCESSWIRE

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Celladon Corp. (NASDAQ:CLDN - News) shares spiked 11.46 percent to close at $11.87 a share Thursday. The stock traded between $11.06 and $13.40 on volume of 820,256 shares traded. The company announced that it has received breakthrough therapy designation by the FDA for its lead product candidate, MYDICAR. Shares of Celladon are up approximately 45.0 percent year-to-date.

Get more information on Celladon and free access to the in-depth equity report at:
www.FiveStarEquities.com/CLDN

Pharmacyclics, Inc. (NASDAQ:PCYC - News) shares dropped 9.59 percent to close at $93.26 a share Thursday. The stock traded between $91.18 and $103.44 on volume of 2.16 million shares traded. The company announced that it has submitted a supplemental New Drug Application to the FDA for IMBRUVICA. Shares of Pharmacyclics are down approximately 12.0 percent year-to-date.

ADVERTISEMENT

Get more information on Pharmacyclics and free access to the in-depth equity report at:
www.FiveStarEquities.com/PCYC

Supercom Ltd. (NASDAQ:SPCB - News) shares surged 12.50 percent to close at $7.29 a share Thursday. The stock traded between $6.41 and $7.62 on volume 1.60 million shares traded. The company announced that it was the winning bidder for contracts amounting to over $25 million from new government customers. Shares of Supercom are up approximately 33.0 percent year-to-date.

Get more information on Supercom and free access to the in-depth equity report at:
www.FiveStarEquities.com/SPCB

Voxeljet AG (NYSE:VJET - News) shares fell 13.44 percent to close at $18.55 a share Thursday. The stock traded between $18.28 and $21.50 on volume 1.25 million shares traded. The company recently announced that it has filed to sell 4.0 million American Depository Shares for a total of $118.8 million. Shares of Voxeljet are down approximately 53.0 percent year-to-date.

Get more information on Voxeljet free access to the in-depth equity report at:
www.FiveStarEquities.com/VJET

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com